207444-91-5

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 10210-17-0 3-(4-hydroxyphenyl)propan-1-ol 

Downstream Products

• 207444-93-7 {4-[3-(Toluene-4-sulfonyloxy)-propyl]-phenoxy}-acetic acid tert-butyl ester 
• 1597430-47-1 3-(4-(tert-butyloxycarbonylmethoxy)phenyl)propyloxyamine hydrochloride 
• 1597430-29-9 3-(4-(tert-butyloxycarbonylmethyloxy)phenyl)propyl bromide 
• 1597430-78-8 C₂₀H₂₅N₃O₉ 
• 1597430-72-2 C₂₄H₃₀N₄O₈ 
• 1597430-70-0 C₂₄H₃₃N₃O₉ 
• 207444-98-2 ((S)-2-{(R)-1-[3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propylcarbamoyl]-2-phenyl-ethylcarbamoyl}-pyrrolidin-1-yl)-oxo-acetic acid methyl ester 
• 207444-97-1 {4-[3-((R)-2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-propyl]-phenoxy}-acetic acid tert-butyl ester 
• 207444-95-9 tert-butyl [4-(3-azidopropyl)phenoxy]acetate 
• 207444-96-0 tert-butyl [4-(3-aminopropyl)phenoxy]acetate 

Relevant academic research and scientific papers

4-alkyloxyimino derivatives of uridine-5′-triphosphate: Distal modification of potent agonists as a strategy for molecular probes of P2Y 2, P2Y4, and P2Y6 receptors

Extended N4-(3-arylpropyl)oxy derivatives of uridine-5′-triphosphate were synthesized and potently stimulated phospholipase C stimulation in astrocytoma cells expressing G protein-coupled human (h) P2Y receptors (P2YRs) activated by UTP (P2Y2/4R) or UDP (P2Y6R). The potent P2Y4R-selective N4-(3- phenylpropyl)oxy agonist was phenyl ring-substituted or replaced with terminal heterocyclic or naphthyl rings with retention of P2YR potency. This broad tolerance for steric bulk in a distal region was not observed for dinucleoside tetraphosphate agonists with both nucleobases substituted. The potent N 4-(3-(4-methoxyphenyl)-propyl)oxy analogue 19 (EC50: P2Y2R, 47 nM; P2Y4R, 23 nM) was functionalized for chain extension using click tethering of fluorophores as prosthetic groups. The BODIPY 630/650 conjugate 28 (MRS4162) exhibited EC50 values of 70, 66, and 23 nM at the hP2Y2/4/6Rs, respectively, and specifically labeled cells expressing the P2Y6R. Thus, an extended N4-(3- arylpropyl)oxy group accessed a structurally permissive region on three G q-coupled P2YRs, and potency and selectivity were modulated by distal structural changes. This freedom of substitution was utilized to design of a pan-agonist fluorescent probe of a subset of uracil nucleotide-activated hP2YRs.

Syntheses of HIV-protease inhibitors having a peptide moiety which binds to GP120

Some HIV-protease inhibitor derivatives having an N- carbomethoxycarbonyl-prolyl-phenylalanine benzyl ester (CPF) moiety as a binding site to gp120 were designed and synthesized. Almost all the compounds bearing CPF on the phenoxyacetyl group showed protease-inhibitory activity. Compounds 25a and 25b, which have the CPF moiety at the ortho- and meta- positions of the phenoxyacetyl group, respectively, had anti-HIV activity, although the others showed only protease-inhibitory activity. These results suggest that 25b binds to gp120 and inhibits HIV protease.